Doximity, Inc.DOCS

Doximity, the digital platform for US medical professionals, hauled in $644.9 million of subscription revenue in the year to 31 March 2026 while booking $196.1 million of net income and producing $326.5 million of operating cash. The balance sheet shows $1.12 billion of assets against $172.8 million of liabilities, leaving $950.8 million of equity and $219.2 million of cash on hand. Crucially, the company spent exactly zero dollars on property, plant, or equipment in the period, a line item that remains stubbornly blank in the cash-flow statement.

The platform’s public story centres on its 3-million-member clinician network, AI-powered tools, and a recruitment arm that promises “direct access to 3M+ U.S. clinicians.” Yet the only hard figures in the evidence are the $16.2 million of new-customer revenue and the $48.4 million of expansion from existing customers. The gap between the recruitment brochure and the subscription ledger is measured in tens of millions.

Filings show $130.7 million of R&D expense and 199.0 million diluted shares outstanding, with earnings per share at $0.98 for the year. The firm’s last proxy reminds investors that the board includes several venture luminaries who helped build a company whose cash pile now exceeds $200 million while capex is stuck at zero. The polished narrative of “helping doctors be more productive” collides with the filing reality: a cash-rich, capex-shy, buyback-averse enterprise that prefers to let equity value sort itself out.

The source rail supplies a steady stream of product pages and press releases, but none of them quantify how many of the 3 million clinicians are actually paying subscribers or how many of the AI features are driving measurable revenue uplift. For now, the numbers that can be proved-revenue, profit, cash, R&D, and share count-sit in stark contrast to the platform’s aspirational messaging.

If you want a chart route, Doximity trades under ticker DOCS on the NYSE. The exchange data feed supplies intraday volume and quote levels, but the evidence gathered here does not include any valuation commentary, moving averages, or technical analysis; those sit beyond the supplied rail.

What changed this week? Insider Form 4 filings on 24 July show directors transacting in modest share lots, while the broader revenue and cash story remains intact and unchanged. The July 15 proxy and 144 filing add governance colour but no new financial metrics. The ARS annual report and press page reaffirm the company’s mission without revising the filings. In short, the operating numbers are stable, the optics are polished, and the capex line stays blank.

What remains unproven? We do not have segment-level revenue splits, customer churn, or product-specific contribution margins. The evidence does not quantify the clinical-AI revenue contribution versus the recruitment or advertising lines. It also does not show any buyback activity or dividend policy. Until the filings supply those details, the picture is cash-rich, capex-light, buyback-silent, and narratively ambitious.